Lyra Therapeutics (LYRA) Projected to Post Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) will likely be releasing its Q1 2026 resultson Tuesday, August 11th. Analysts expect the company to announce earnings of ($1.54) per share and revenue of $0.10 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:00 PM ET.

Lyra Therapeutics Price Performance

LYRA stock remained flat at $0.47 during mid-day trading on Tuesday. The company’s stock had a trading volume of 22 shares, compared to its average volume of 53,314. The firm’s 50 day simple moving average is $0.60 and its two-hundred day simple moving average is $0.92. Lyra Therapeutics has a 52-week low of $0.00 and a 52-week high of $8.75. The company has a market cap of $843,125.00, a PE ratio of -0.02 and a beta of 0.68.

Institutional Trading of Lyra Therapeutics

Several hedge funds have recently added to or reduced their stakes in LYRA. DRW Securities LLC bought a new stake in Lyra Therapeutics in the fourth quarter valued at approximately $52,000. Citadel Advisors LLC bought a new position in shares of Lyra Therapeutics in the third quarter worth approximately $128,000. Finally, Bank of America Corp DE grew its holdings in shares of Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after purchasing an additional 7,190 shares during the last quarter. 95.62% of the stock is owned by institutional investors.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).